Physician profile
Ashley Alex
NPI 1295198331
$1,126.00
in general payments reported to CMS, 2019-2025
14 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.39 · 2022: $233 · 2023: $250 · 2024: $161 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.55 | 2021-2025 | Botox, Qulipta |
| Mdd US Operations, LLC | $208.01 | 2023-2025 | Gocovri, Gocovri |
| Sanofi-Aventis U.S. LLC | $124.99 | 2022 | |
| Supernus Pharmaceuticals, INC. | $72.28 | 2025 | Qelbree |
| Merz Pharmaceuticals, LLC | $57.00 | 2024-2025 | Xeomin, Inbrija |
| Pfizer INC. | $54.46 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $39.29 | 2025 | |
| Csl Behring | $34.57 | 2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $31.61 | 2022 | |
| Ucb, INC. | $30.37 | 2025 | Fintepla |
| Medtronic, INC. | $26.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.13 | 2025 | |
| Vanda Pharmaceuticals INC. | $14.91 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Alex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.